Scarica l'app Stockscreener
4.78
0.83%
-0.04
Precedente Chiudi:
$4.82
Aprire:
$4.82
Volume 24 ore:
1.20M
Relative Volume:
1.11
Capitalizzazione di mercato:
$382.78M
Reddito:
$116.30M
Utile/perdita netta:
$17.73M
Rapporto P/E:
22.76
EPS:
0.21
Flusso di cassa netto:
$20.88M
1 W Prestazione:
-5.53%
1M Prestazione:
-7.00%
6M Prestazione:
-50.26%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.715
$4.939
Intervallo di 1 settimana:
$4.715
$5.395
Portata 52W:
$4.715
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
4.78 | 382.78M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Analyst Calls: Can Niagen Bioscience Inc stock outperform in a bear marketRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Chart Watch: Is Niagen Bioscience Inc stock risky to hold nowMarket Volume Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Niagen Bioscience (NAGE) Earnings Transcript - AOL.com
Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line - MSN
Niagen Bioscience Launches Niagen Skincare Innovation Lab - Happi | Household And Personal Products Industry
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen - itemonline.com
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen® - Business Wire
Earnings call transcript: Niagen Bioscience’s Q4 2025 revenue grows 16% - Investing.com Nigeria
Risk Off: Is now the right time to enter Niagen Bioscience Inc2026 Momentum & Risk Managed Investment Signals - baoquankhu1.vn
Is Niagen Bioscience Inc. (OCD1) stock undervalued historically2026 Top Gainers & Safe Entry Trade Reports - Naître et grandir
Sentiment Review: Can Niagen Bioscience Inc be recession proofTrade Entry Report & Safe Entry Trade Reports - baoquankhu1.vn
Why Niagen Bioscience Inc. stock appeals to dividend seekersForecast Cut & Low Risk High Reward Ideas - Naître et grandir
Niagen Bioscience (NASDAQ:NAGE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Value Recap: Will Niagen Bioscience Inc stock hit new highs in YEAR - baoquankhu1.vn
Niagen Bioscience (NAGE) Margin Rise To 13.4% Tests Bullish Narrative Targets - simplywall.st
Niagen Bioscience FY25 Net Sales Jump 30%; Sees 10-15% Growth In FY26 - Nasdaq
Canaccord Genuity Group Cuts Niagen Bioscience (NASDAQ:NAGE) Price Target to $13.00 - MarketBeat
Niagen Bioscience 2025 Financials: $129.4M Revenue, $17.4M ProfitNews and Statistics - IndexBox
Niagen Bioscience (NAGE) Valuation Check After Strong 2025 Results And Moderated 2026 Growth Outlook - simplywall.st
Niagen Bioscience Rallies 18% After Hours: Here's Why - Benzinga
Earnings call transcript: Niagen Bioscience’s Q4 2025 revenue grows 16% By Investing.com - Investing.com South Africa
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED) - Benzinga
NAGE Earnings History & Surprises | EPS & Revenue Results | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience Inc (NAGE) Q4 2025 Earnings Call Highlights: S - GuruFocus
Niagen Bioscience earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Niagen Bioscience (NAGE) Reports Strong Q4 and Ambitious 2026 Pl - GuruFocus
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income I - PharmiWeb.com
Niagen Bioscience (NAGE) Surges 39% Following Q4 Results and Pos - GuruFocus
Niagen Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Niagen Bioscience (NAGE) Surpasses Q4 Revenue Expectations - GuruFocus
Niagen Bioscience Reports Strong 2025 Results, Strategic Shift - TipRanks
Niagen Bioscience soars 38% on blowout Q4 results By Investing.com - Investing.com Canada
Niagen Bioscience Q4 Earnings Assessment - Benzinga
Niagen Bioscience soars 38% on blowout Q4 results - Investing.com South Africa
Niagen Bioscience: Q4 Earnings Snapshot - kens5.com
Niagen Bioscience: Fourth Quarter Financial Overview - Bitget
Niagen Bioscience announces financial results for fourth quarter and fiscal 2025, ChromaDex Corp. states - Traders Union
BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million - TradingView
Niagen Bioscience more than doubles 2025 profit as Tru Niagen sales jump - Stock Titan
Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 205% Upside in the Biotech Sector - DirectorsTalk Interviews
EPS Watch: Is Niagen Bioscience Inc a cyclical or defensive stockWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Niagen Bioscience sells reference standards unit to LGC By Investing.com - Investing.com Canada
Niagen Bioscience to streamline operations with the sale of Chromadex reference standards business to LGC - marketscreener.com
VHG Labs, Inc. acquired ChromaDex's analytical reference standards and services business from Niagen Bioscience, Inc.. - marketscreener.com
Niagen Bioscience sells reference standards unit to LGC - Investing.com
Niagen Bioscience Divests Non-Core Analytical Standards Business - TipRanks
Niagen Bioscience To Streamline Operations With The Sale Of Chromadex Reference Standards Business To LGC - TradingView
Niagen Bioscience sells ChromaDex reference standards business to LGC in all-cash deal - TradingView
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction - Business Wire
Niagen Bioscience secures patent for IV NAD+ precursor delivery - Investing.com India
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):